IDiyas

For the Inventor, By the Inventor

Warren, NJ, United States of America

David Askin

USPTO Granted Patents = 29 

Average Co-Inventor Count = 4.4

ph-index = 7

Forward Citations = 144(Granted Patents)


Location History:

  • Edison, NJ (US) (1989 - 1995)
  • Warren, NJ (US) (1992 - 2009)

Company Filing History:

goldMedal29 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1989-2009

Loading Chart...
29 patents (USPTO):
1. 7598264 - HIV integrase inhibitors (2009-10-06),
2. 6642237 - Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof (2003-11-04),
3. 6388083 - Process for the synthesis of (2S)-phenyl-3-piperidone (2002-05-14),
4. 6239280 - Process for synthesizing biaryl inhibitors of farnesyl-protein transferase (2001-05-29),
5. 6160118 - Process for the synthesis of substituted piperazinones via Mitsunobu (2000-12-12),
6. 6140508 - Process for making 1,5-disubstituted imidazoles (2000-10-31),
7. 6071916 - HIV protease inhibitor (2000-06-06),
8. 5929243 - Process for the preparation of (S)-3-carbethoxy-3-benzylpiperidine (1999-07-27),
9. 5861512 - Process for making HIV protese inhibitors (1999-01-19),
10. 5728840 - Process for making an epoxide (1998-03-17),
11. 5723615 - Process for preparing (1998-03-03),
12. 5693803 - Process for making HIV protease inhibitors (1997-12-02),
13. 5663341 - Process for making HIV protease inhibitors (1997-09-02),
14. 5637711 - Process for making HIV protease inhibitors (1997-06-10),
15. 5618939 - Process for making HIV protease inhibitors (1997-04-08),

Title: David Askin: Pioneering Innovations in HIV Treatment

Introduction:

David Askin, a pioneering inventor based in Warren, NJ, has been at the forefront of technological advancements in the medical field. His relentless passion for innovation and drive to push boundaries have solidified his position as a prominent figure in the world of technology, particularly in the realm of HIV treatment.

Latest Patents:

Askin has an impressive portfolio of 29 patents, with his latest patents focusing on groundbreaking advancements in the treatment of HIV. His inventions include HIV integrase inhibitors and gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides, which have shown promising results in inhibiting HIV replication and treating AIDS.

Career Highlights:

David Askin is a valuable asset to Merck & Company, Inc., a leading pharmaceutical company. Through his innovative work, he has played a pivotal role in developing cutting-edge treatments for HIV and AIDS. His dedication to advancing medical science has earned him recognition as a key player in the field.

Collaborations:

Throughout his career, David Askin has collaborated with esteemed colleagues such as Ralph P. Volante and Paul J. Reider. Their collective expertise and collaborative efforts have led to significant advancements in the field of HIV treatment, paving the way for improved patient outcomes and better treatment options.

Conclusion:

David Askin's groundbreaking inventions and commitment to innovation have made a significant impact on the field of HIV treatment. His contributions continue to inspire and shape the future of medical technology, offering hope to patients worldwide. Askin's pioneering spirit serves as a beacon for aspiring inventors and underscores the importance of relentless drive in pushing the boundaries of what is possible in the world of technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…